Thor Halfdanarson/mayoclinic.org
Apr 12, 2025, 06:07
Thor Halfdanarson: Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia
Thor Halfdanarson, Medical Oncologist at Mayo Clinic, shared a post on X:
“Refractory hypoglycemia in patients with metastatic insulinoma is a major challenge but usually controllable with SSAs, everolimus, PRRT and regional therapy.
I have not given diazoxide in >10 years but maybe I should consider pasireotide more often…”
“Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.”
Authors: Arturo Vega-Beyhart, Betina Biagetti, Mónica Marazuela, Manel Puig-Domingo, Marta Araujo-Castro
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 15:35
May 10, 2025, 15:01
May 10, 2025, 15:01
May 10, 2025, 14:14
May 10, 2025, 14:11
May 10, 2025, 13:57